While EGFR-targeted therapies employing the monoclonal antibody cetuximab are already included in the standard repertoire of HNSCC treatment, the efficacy of FGFR-inhibition still needs to be determined. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.